Infliximab neutralizes soluble TNF-α and blocks TNFR1/2 signaling, reducing inflammation; it does not bind a cell-surface target on TNF-secreting cells, so no direct ADCC/CDC-mediated killing. (Direct cytotoxicity occurs only when binding transmembrane TNF.)